drugset / Trial / NCT02597998
Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to assess the mass balance recovery from excreta of carbon 14 labelled BI409306 (\[14C\] BI 409306) in healthy, CYP2C19 genotyped subjects and to provide plasma, urine and faecal samples for metabolite profiling and structural identification.
Timeline
- Start
- 2015-09-15
- Primary completion
- 2015-12-11
- Completion
- 2015-12-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OSORESNONTRINE | Small molecule | 25 mg | Oral |
Indications
No indication recorded.